Recent Articles

Effective Solutions

Effective Solutions

| November 20, 2012 | 0 Comments

Introducing the EVOX performance enhancement system. The EVOX delivers highly-predictable, thorough, and consistent results for a variety of issues dealing with subconscious stress, and PTSD appears to be no exception. The EVOX measures voice frequencies during a brief recording of the client’s voice. It captures reliable markers of subconscious stress and displays a pattern on […]

Continue Reading

The Challenge of Treating PTSD

The Challenge of Treating PTSD

| November 20, 2012 | 0 Comments

Continue Reading

PTSD and the “Hot Stove” Effect

PTSD and the “Hot Stove” Effect

| November 20, 2012 | 0 Comments

The basic cause of PTSD is no mystery. Traumatic experiences trigger what I call the “hot stove effect,” which happens like this: if a child touches a hot stove and burns his hand, the subconscious creates an association between the hot stove and the ensuing pain and injury. The next time it recognizes a hot […]

Continue Reading

A Sense of Urgency

A Sense of Urgency

| November 20, 2012 | 0 Comments

Due largely to the large number of soldiers who suffer from combat stress and the difficulty of treating PTSD, Post Traumatic Stress Disorder (or PTSS – Post Traumatic Stress Syndrome) has become one of the most urgent issues facing the military medical establishment. Known as “shell shock” in earlier wars, PTSD became better known following […]

Continue Reading

Faster, Easier, Better Results

Faster, Easier, Better Results

| November 20, 2012 | 0 Comments

The bioenergetic technology field – with specific applications for medicine, counseling and performance enhancement – is booming. Significant developments over the past decade have raised the bar, and if you’re a medical professional or a patient wanting the best possible care, it’s time you got informed.

Continue Reading

Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH

| April 13, 2015 | 0 Comments

Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).

Continue Reading

Earthly Extremophiles Prompt Speculation about Alien Life

Earthly Extremophiles Prompt Speculation about Alien Life

| March 9, 2015 | 0 Comments

Discovery of fish under Antarctic ice may provide clues about ecosystems on Jupiter’s moon Europa and other extraterrestrial environments — Read more on ScientificAmerican.com

Continue Reading

New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability

New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability

| January 13, 2015 | 0 Comments

New Vital Force Technology results show that subtle energy patterns have a significant positive impact on human cell growth. (PRWeb January 13, 2015) Read the full story at http://www.prweb.com/releases/2015/NewSubtleEnergyFindings/prweb12439444.htm

Continue Reading

Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …

Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …

| November 13, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 …

Continue Reading

Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

| November 6, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced positive data from an ongoing Phase …

Continue Reading

Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …

Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …

| October 21, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical …

Continue Reading

Seahorse Bioscience and University of Alabama at Birmingham Partner to Advance Validation of Bioenergetic Health Index …

Seahorse Bioscience and University of Alabama at Birmingham Partner to Advance Validation of Bioenergetic Health Index …

| October 15, 2014 | 0 Comments

BILLERICA, Mass., Oct.

Continue Reading

Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

| October 7, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I clinical trial evaluating CPI-613 …

Continue Reading

Study: Higher education doesn't drive people from religion

Study: Higher education doesn't drive people from religion

| August 11, 2014 | 0 Comments

For decades, higher education has often been cast as the villain in the story of U.S. religious decline. Past research supported these claims.

Continue Reading

Researchers create experimental blood test to determine BHI by gauging performance of mitochondria

Researchers create experimental blood test to determine BHI by gauging performance of mitochondria

| May 30, 2014 | 0 Comments

Researchers at the University of Alabama at Birmingham School of Medicine have created an experimental blood test that, for the first time, determines a “Bioenergetic Health Index,” or BHI, by gauging the performance of mitochondria, the cell's energy powerhouses.

Continue Reading